Chase Investment Counsel Corp Supernus Pharmaceuticals, Inc. Transaction History

Chase Investment Counsel Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 07, 2018	SELL	$37.15 - $46.9 $414,036 - $522,700	-11,145 Closed	0 $0
Q4 2017 Feb 05, 2018	SELL	$36.4 - $42.6 $16,380 - $19,170	-450 Reduced 3.88%	11,145 $444,000
Q3 2017 Nov 03, 2017	BUY	$36.75 - $49.65 $426,116 - $575,691	11,595	11,595 $463,000

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Chase Investment Counsel Corp, based on Form 13F filings with the SEC.

Stay updated on Chase Investment Counsel Corp with notifications on news.